Human IRF7 knockout A549 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
IRF7 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 11 bp deletion in exon3.
View Alternative Names
IMD39, IRF 7A, IRF 7H, IRF7B, IRF7C, IRF7_HUMAN, Interferon regulatory factor 7, Interferon regulatory factor 7H
- Sanger seq
Unknown
Sanger Sequencing - Human IRF7 knockout A549 cell lysate (AB258928)
Homozygous : 11 bp deletion in exon3
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Zygosity
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF7 activates and modulates the expression of type I interferons and other cytokines important for antiviral defense. This protein can form part of a larger complex with other IRF family members to enhance its effect on gene transcription. IRF7 operates through its interaction with transcriptional coactivators allowing it to execute its function as a transcriptional activator reinforcing the immune system's response to infectious agents.
Pathways
IRF7 plays a critical role in the Toll-like receptor (TLR) signaling pathway and retinoic acid-inducible gene I (RIG-I) pathway. It directly interacts with MyD88 and IRAK1 proteins linking it to signal transduction pathways that lead to interferon-beta production. The activation of IRF7 in these pathways also strengthens the body's defense mechanism by enhancing the transcription of antiviral genes forming a robust antibacterial and antiviral environment within the host.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
![Western blot - Anti-IRF7 antibody [EPR23509-21] (AB238137)](https://content.abcam.com/products/images/irf7-antibody-epr23509-21-ab238137--western-blot-img11365.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com